Boston Partners Boosts Holdings in Chemed Corporation $CHE

Boston Partners boosted its Chemed stake 37.1% to 22,651 shares (~$11.03M) amid very high institutional ownership (95.85%), while insiders have sold 5,150 shares in the last 90 days including CEO Kevin McNamara's 3,000-share sale. Chemed reported $5.27 EPS on $624.90M revenue (misses of $0.12 and ~$1.14M vs. estimates), with net margin 11.02% and ROE 25.89%; management set FY2025 guidance of $22.00–22.30 EPS versus analyst consensus ~21.43, and declared a $0.60 quarterly dividend (annualized $2.40, 0.5% yield).

Analysis

Market structure: Chemed is a two-legged business where VITAS (aged-care hospice) provides defensive, high-margin recurring cash flow while Roto-Rooter ties revenue to housing/maintenance cycles. Institutional buying (Boston Partners + others) and 95.9% institutional ownership compress float and can amplify directional moves; current P/E 23.2 vs historical highs implies ~25–30% upside to the $574 consensus target if multiples re-rate. Cross-asset: low beta (0.43) and stable cashflow make CHE bond-like—insensitive to short-term rates but vulnerable to long-duration multiple compression if yields rise sharply.

Risk assessment: Primary tail risks are an unexpected CMS/Medicare reimbursement cut (>10–20% headwind to hospice margins), major litigation, or a sustained housing downturn reducing Roto-Rooter volumes by >10% YoY. Timeline: immediate (days) — stock sensitive to insider/analyst headlines; short-term (next 1–3 quarters) — earnings vs guidance and winter seasonality for hospice; long-term (≥12 months) — demographic-driven growth assuming margin stability. Hidden dependency: Roto-Rooter revenues lag housing activity by ~6–12 months, so rising rates today may bite that segment later.

Trade implications: Tactical play: establish a 2–3% long position in CHE at market (~$439) or scale in on pullbacks to $410–420, target $560–600 in 9–12 months, hard stop at $380 (limit downside to ~12–14%). Options: buy a 9–12 month call spread (e.g., buy Jan 2026 $440 call, sell Jan 2026 $600 call) sized to equal 1–2% portfolio risk to capture re-rating with defined max loss. Relative value: pair long CHE vs short HD (0.4x notional) to isolate VITAS defensive exposure vs home-improvement cyclicality ahead of potential housing slowdown.

Contrarian angles: Consensus (~$574 TP) may underweight secular hospice margins; CEO sales (3,000 shares) look like normal liquidity/option exercise, not a material vote of no-confidence given 3.29% insider ownership and institutional accumulation. The market may be underpricing the stability of hospice cash flows—if CHE holds guidance (22.00–22.30 EPS), a re-rating to 25–26x is plausible; conversely, forced outsized moves could occur because high institutional ownership reduces retail float, so size positions conservatively and use options to cap tail losses.

Key Decisions for Investors

• Establish a 2–3% long position in CHE (NYSE:CHE) at current market (~$439) or scale in on dips to $410–420; set a target sell range $560–600 within 9–12 months and a hard stop-loss at $380.
• Buy a defined-risk 9–12 month call spread: buy Jan 2026 $440 call and sell Jan 2026 $600 call, position sizing to risk no more than 1–2% of portfolio to capture potential re-rating if guidance holds.
• Implement a pair trade: go long CHE (size X) and short HD (size 0.4X) to isolate VITAS defensive exposure versus housing-cycle sensitivity; rebalance after next two quarterly earnings based on Roto-Rooter volumes.
• Avoid outright large long exposure (>5% portfolio) until next Medicare/CMS guidance window passes (monitor CMS rulemaking and any hospice reimbursement commentary over next 60–120 days); if CMS signals >5% reimbursement cut, close long and trim to zero.